A combination of the telomerase inhibitor, BIBR1532, and paclitaxel synergistically inhibit cell proliferation in breast cancer cell lines

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Targeted oncology

• Publication date

  2015-04-29

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s11523-015-0364-yPMID 25916999
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cytotoxicity of Paclitaxel in Breast Cancer Is due to Chromosome Missegregation on Multipolar Spindles

  2014cited by this paper
• Telomerase inhibition by non-nucleosidic compound BIBR1532 causes rapid cell death in pre-B acute lymphoblastic leukemia cells

  2013cited by this paper
• Structure–function relationship and biogenesis regulation of the human telomerase holoenzyme

  2013cited by this paper
• BIBR 1532 increases arsenic trioxide-mediated apoptosis in acute promyelocytic leukemia cells: therapeutic potential for APL.

  2013cited by this paper
• Structure of Active, Dimeric Human Telomerase

  2013cited by this paper
• Telomerase reactivation following telomere dysfunction yields murine prostate tumors with bone metastases.

  2012cited by this paper
• Potential of telomerase activation in extending health span and longevity.

  2012cited by this paper
• It all comes together at the ends: telomerase structure, function, and biogenesis.

  2012cited by this paper
• Recent patents on anti-telomerase cancer therapy.

  2012cited by this paper
• Universal Cancer Peptide-Based Therapeutic Vaccine Breaks Tolerance against Telomerase and Eradicates Established Tumor

  2012cited by this paper
• Telomere structure and telomerase in health and disease

  2012cited by this paper
• Is telomerase a viable target in cancer?

  2012cited by this paper
• HIV-Tat-mediated delivery of an LPTS functional fragment inhibits telomerase activity and tumorigenicity of hepatoma cells.

  2011cited by this paper
• Global cancer statistics

  2011cited by this paper
• Telomerase structure function.

  2011cited by this paper
• Telomerase: Structure, functions, and activity regulation

  2010cited by this paper
• Imetelstat (GRN163L)--telomerase-based cancer therapy.

  2010cited by this paper
• The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances taxol-induced cell death in breast cancer

  2010cited by this paper
• Telomerase inhibition potentiates the effects of genotoxic agents in breast and colorectal cancer cells in a cell cycle-specific manner.

  2010cited by this paper
• EGFR Signaling and Drug Discovery

  2010cited by this paper
• Microtubules and resistance to tubulin-binding agents

  2010cited by this paper
• Microtubules and resistance to tubulin-binding agents

  2010cited by this paper
• Telomerase structure paves the way for new cancer therapies.

  2009cited by this paper
• The telomerase template antagonist GRN163L alters MDA-MB-231 breast cancer cell morphology, inhibits growth, and augments the effects of paclitaxel

  2009cited by this paper
• siRNA inhibition of telomerase enhances the anti-cancer effect of doxorubicin in breast cancer cells

  2009cited by this paper
• Telomere maintenance and dysfunction predict recurrence in paediatric ependymoma

  2008cited by this paper
• Telomere dysfunction and tumour suppression: the senescence connection

  2008cited by this paper
• Targeting cyclin B1 inhibits proliferation and sensitizes breast cancer cells to taxol

  2008cited by this paper
• Targeting telomerase for cancer therapeutics

  2008cited by this paper
• Telomerase inhibitor GRN163L inhibits myeloma cell growth in vitro and in vivo

  2008cited by this paper
• Telomerase targeted oligonucleotide thio‐phosphoramidates in T24‐luc bladder cancer cells

  2008cited by this paper
• Telomerase and cancer therapeutics

  2008cited by this paper
• Structure of the Tribolium castaneum telomerase catalytic subunit TERT

  2008cited by this paper
• Specific telomere dysfunction induced by GRN163L increases radiation sensitivity in breast cancer cells.

  2007cited by this paper
• Oligonucleotide Conjugate GRN163L Targeting Human Telomerase as Potential Anticancer and Antimetastatic Agent

  2007cited by this paper
• Telomerase inhibition enhances the response to anticancer drug treatment in human breast cancer cells

  2006cited by this paper
• Telomerase Template Antagonist GRN163L Disrupts Telomere Maintenance, Tumor Growth, and Metastasis of Breast Cancer

  2006cited by this paper
• Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer

  2006cited by this paper
• Effects of a novel telomerase inhibitor, GRN163L, in human breast cancer

  2006cited by this paper
• Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies

  2006influential reference
• In vivo inhibition of lung cancer by GRN163L: a novel human telomerase inhibitor.

  2005cited by this paper
• Breast cancer susceptibility and the DNA damage response.

  2005cited by this paper
• Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.

  2005cited by this paper
• Selective cytotoxicity and telomere damage in leukemia cells using the telomerase inhibitor BIBR1532.

  2005cited by this paper
• Statistics on cancer in China: cancer registration in 2002

  2005cited by this paper
• Pharmacological Telomerase Inhibition Can Sensitize Drug-Resistant and Drug-Sensitive Cells to Chemotherapeutic Treatment

  2005cited by this paper
• Global Cancer Statistics, 2002

  2005cited by this paper
• Telomerase and cancer.

  2001cited by this paper
• Taxol-induced cell cycle arrest and apoptosis: dose-response relationship in lung cancer cells of different wild-type p53 status and under isogenic condition.

  2001cited by this paper
• A highly selective telomerase inhibitor limiting human cancer cell proliferation

  2001cited by this paper
• Paclitaxel, 5-fluorouracil, and leucovorin (TFL) in the treatment of metastatic breast cancer.

  2000cited by this paper
• Commentary on “Paclitaxel, 5-Fluorouracil, and Leucovorin (TFL) in the Treatment of Metastatic Breast Cancer”

  2000cited by this paper
• Erratum: Effects of p21(Cip1/Waf1) at both the G1/S and the G2/M cell cycle transitions: pRb is a critical determinant in blocking DNA replication and in preventing endoreduplication (Molecular and Cellular Biology 18:1 (629))

  1998cited by this paper
• Effects of p21Cip1/Waf1 at Both the G1/S and the G2/M Cell Cycle Transitions: pRb Is a Critical Determinant in Blocking DNA Replication and in Preventing Endoreduplication

  1998cited by this paper
• Telomerase and cancer.

  1997cited by this paper
• Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.

  1984cited by this paper

• The impact of the telomerase inhibitor on the Wnt signaling pathway in breast cancer and breast cancer stem cells

  2026cites this paper
• Global research trends and prospects related to telomerase within breast cancer: a bibliometric and visual analysis

  2025cites this paper
• Combined Inhibition of telomerase and mitochondria synergistically promote apoptosis in AML cell lines

  2025cites this paper
• Improving therapeutic strategies for triple-negative breast cancer: synergistic effects of DKC1 inhibition and paclitaxel

  2025cites this paper
• Telomerase inhibitors - TMPyP4, BIBR 1532 and imetelstat - alter the adhesion potential of breast cancer MCF7 and MDA-MB-231 cells that leads to impaired ability to form spheroids

  2025cites this paper
• Telomerase inhibitors TMPyP4 and BIBR 1532 show synergistic antitumor activity in combination with chemotherapeutic drugs

  2025cites this paper
• Broad-spectrum antitumor analysis of the telomerase activity inhibitor TPCH derived from the human constitutively expressed protein LPTS/PinX1

  2025cites this paper
• Natural killer cells in combination with the inhibition of telomerase induced apoptosis in Acute Myeloid Leukemia cells

  2025cites this paper
• Role of p53 transcription factor in determining the efficacy of telomerase inhibitors in cancer treatment.

  2024cites this paper
• Telomerase inhibition in breast cancer and breast cancer stem cells: a brief review

  2024cites this paper
• Enhanced induction of apoptosis in chronic myeloid leukemia cells through synergistic effect of telomerase inhibitor MST-312 and imatinib

  2024cites this paper
• Investigation of cytotoxic effect and action mechanism of a synthetic peptide derivative of rabbit cathelicidin against MDA-MB-231 breast cancer cell line

  2024cites this paper
• Preparation and anticancer activity of telomerase inhibitor TAT-LPTS39 polypeptide

  2024cites this paper
• Zeolitic Imidazolate Framework-8 (ZIF-8) as a Drug Delivery Vehicle for the Transport and Release of Telomerase Inhibitor BIBR 1532

  2023cites this paper
• Telomerase and mitochondria inhibition promote apoptosis and TET2 and ANMT3a expression in triple negative breast cancer cell lines

  2023cites this paper
• Retrospective Analysis of the Clinical Characteristics of Patients with Breast Cancer Treated with Telomerase Peptide Immunotherapy Combined with Cytotoxic Chemotherapy

  2023cites this paper
• Regulation of telomerase towards tumor therapy

  2023cites this paper
• Deciphering the Functions of Telomerase Reverse Transcriptase in Head and Neck Cancer

  2023cites this paper
• Regulation and clinical potential of telomerase reverse transcriptase (TERT/hTERT) in breast cancer

  2023cites this paper
• Research progress of small-molecule drugs in targeting telomerase in human cancer and aging.

  2023cites this paper
• An update on paclitaxel treatment in breast cancer

  2022cites this paper
• The Small Molecule BIBR1532 Exerts Potential Anti-cancer Activities in Preclinical Models of Feline Oral Squamous Cell Carcinoma Through Inhibition of Telomerase Activity and Down-Regulation of TERT

  2021cites this paper
• hTERT Downregulation Attenuates Resistance to DOX, Impairs FAK-Mediated Adhesion, and Leads to Autophagy Induction in Breast Cancer Cells

  2021cites this paper
• Shikonin N-benzyl matrinic acid ester derivatives as novel telomerase inhibitors with potent activity against lung cancer cell lines.

  2021cites this paper
• Arsenic trioxide and BIBR1532 synergistically inhibit breast cancer cell proliferation through attenuation of NF-κB signaling pathway.

  2020cites this paper
• Biological behavior exploration of a paclitaxel-eluting poly-l-lactide-coated Mg–Zn–Y–Nd alloy intestinal stent in vivo

  2020cites this paper
• Structural Features of Nucleoprotein CST/Shelterin Complex Involved in the Telomere Maintenance and Its Association with Disease Mutations

  2020cites this paper
• Potential Telomere-Related Pharmacological Targets.

  2020cites this paper
• Telomerase: key regulator of inflammation and cancer.

  2020cites this paper
• Targeting telomerase for its advent in cancer therapeutics.

  2020cites this paper
• Telomerase Inhibitor TMPyP4 Alters Adhesion and Migration of Breast-Cancer Cells MCF7 and MDA-MB-231

  2019cites this paper
• Label-Free Telomerase Detection in Single Cell Using a Five-Base Telomerase Product-Triggered Exponential Rolling Circle Amplification Strategy.

  2019cites this paper
• Quartz crystal microbalance for telomerase sensing based on gold nanoparticle induced signal amplification.

  2019cites this paper
• Luteolin inhibits cell cycle progression and induces apoptosis of breast cancer cells through downregulation of human telomerase reverse transcriptase

  2019cites this paper
• Contributory role of microRNAs in anti‐cancer effects of small molecule inhibitor of telomerase (BIBR1532) on acute promyelocytic leukemia cell line

  2019cites this paper
• The telomerase inhibitor MST-312 synergistically enhances the apoptotic effect of doxorubicin in pre-B acute lymphoblastic leukemia cells.

  2018cites this paper
• Correlation between telomerase and mTOR pathway in cancer stem cells.

  2018cites this paper
• Effects of telomerase inhibitor on epigenetic chromatin modification enzymes in malignancies

  2018cites this paper
• Down regulation of human telomerase reverse transcriptase (hTERT) expression by BIBR1532 in human glioblastoma LN18 cells

  2018cites this paper
• Investigation of the effect of telomerase inhibitor BIBR1532 on breast cancer and breast cancer stem cells

  2018cites this paper
• Targeting human telomerase RNA component using antisense oligonucleotide induces rapid cell death and increases ATO‐induced apoptosis in APL cells

  2017cites this paper
• Characterisation of the selectivity and binding interactions of berberine derivatives with G-quadruplex DNA and a DNA/RNA hybrid

  2017cites this paper
• Synergistic Anticancer Effects of Silibinin and Chrysin in T47D Breast Cancer Cells

  2017cites this paper
• Inhibition of telomerase potentiates enzalutamide efficiency of androgen-sensitive human prostate cancer cells.

  2017cites this paper
• Telomerase reverse transcriptase mediates EMT through NF-κB signaling in tongue squamous cell carcinoma

  2017cites this paper
• Targeting telomerase and telomeres to enhance ionizing radiation effects in in vitro and in vivo cancer models.

  2017cites this paper
• Erratum to: A combination of the telomerase inhibitor, BIBR1532, and paclitaxel synergistically inhibit cell proliferation in breast cancer cell lines

  2017cites this paper
• Inhibition of telomerase using BIBR1532 enhances doxorubicin-induced apoptosis in pre-B acute lymphoblastic leukemia cells

  2017cites this paper
• Tumor-selective peptide-carrier delivery of Paclitaxel increases in vivo activity of the drug

  2015cites this paper
• Knockdown of hTERT and Treatment with BIBR1532 Inhibit Cell Proliferation and Invasion in Endometrial Cancer Cells

  2015influential citation